A Novel Approach for Preventing Recurrence of Malign Pleural Effusion: Early Phase Pleurodesis

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2018 Nov 6

PMID 30393496

Authors

Ufuk Cobanoglu

Ozgur Kemik

Sebahattin Celik

Fuat Sayir

Affiliations

Soon will be listed here.

Abstract

Introduction: The effective control of malignant pleural effusion (MPE) is of paramount importance in the treatment of patients with disseminated cancer. In this study, we compared two different approaches (early pleurodesis versus late pleurodesis) to MPE.

Material And Methods: Patients (188 cases) whose primary tumor type was known and who were confirmed to have MPE, were included in the study and were separated into two groups. One group consisted of patients who were asymptomatic and who underwent early phase pleurodesis (group I, = 79). The other group (group II, = 109) was composed of patients who were symptomatic and whose pleurodesis was performed later. In all cases, pleural effusion was evaluated by means of direct radiography. Computed tomography was performed with the goal of confirming the parenchymal or mediastinal lesions accompanying the pleural fluid.

Results: The rate of complete success in group I cases was observed to be higher, while the rate of recurrence was lower ( = 0.001 and = 0.002, respectively) than group II. In multiple logistic regression analysis, co-morbidities and the group that patient belong were found to be significant in terms of pleurodesis success ( = 0.02 and = 0.03). There was a significant difference in survival time between group I and group II, with group I exhibiting longer average survival time (log rank test < 0.001).

Conclusions: We observed that the success rate was lower and the rate of recurrence higher in the late pleurodesis group, whose members already had greater volumes of pleural effusion.

References

Szychta P, Westfal B, Maciejczyk R, Smolarz B, Romanowicz H, Krawczyk T . Intraoperative diagnosis of sentinel lymph node metastases in breast cancer treatment with one-step nucleic acid amplification assay (OSNA). Arch Med Sci. 2016; 12(6):1239-1246. PMC: 5108387. DOI: 10.5114/aoms.2016.62902. View

Marel M, Fila L, cervena M . [The differential diagnosis of pleural effusions]. Vnitr Lek. 2016; 62(7-8):598-604. View

Bernard A, de Dompsure R, Hagry O, Favre J . Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg. 2002; 74(1):213-7. DOI: 10.1016/s0003-4975(02)03599-3. View

Hunt B, Farivar A, Vallieres E, Louie B, Aye R, Flores E . Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg. 2012; 94(4):1053-7. DOI: 10.1016/j.athoracsur.2012.01.103. View

Fysh E, Waterer G, Kendall P, Bremner P, Dina S, Geelhoed E . Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest. 2012; 142(2):394-400. DOI: 10.1378/chest.11-2657. View

Ferreiro L, Suarez-Antelo J, Valdes L . Pleural procedures in the management of malignant effusions. Ann Thorac Med. 2017; 12(1):3-10. PMC: 5264169. DOI: 10.4103/1817-1737.197762. View

Poyraz N, Kalkan H, Odev K, Ceran S . [Imaging of pleural diseases: evaluation of imaging methods based on chest radiography]. Tuberk Toraks. 2017; 65(1):41-55. DOI: 10.5578/tt.47546. View

Santos P, Marques M, Cruz C, Monteiro H, Fradinho F . Predictors of talc slurry pleurodesis success in patients with malignant pleural effusions. Rev Port Pneumol (2006). 2017; 23(4):216-220. DOI: 10.1016/j.rppnen.2017.01.008. View

Rajwa P, Zyczkowski M, Paradysz A, Slabon-Turska M, Suliga K, Bujak K . Novel hematological biomarkers predict survival in renal cell carcinoma patients treated with nephrectomy. Arch Med Sci. 2020; 16(5):1062-1071. PMC: 7444725. DOI: 10.5114/aoms.2017.70250. View

10.

Agarwal R, Paul A, Aggarwal A, Gupta D, Jindal S . A randomized controlled trial of the efficacy of cosmetic talc compared with iodopovidone for chemical pleurodesis. Respirology. 2011; 16(7):1064-9. DOI: 10.1111/j.1440-1843.2011.01999.x. View

11.

Clive A, Kahan B, Hooper C, Bhatnagar R, Morley A, Zahan-Evans N . Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014; 69(12):1098-104. PMC: 4251306. DOI: 10.1136/thoraxjnl-2014-205285. View

12.

Steger V, Mika U, Toomes H, Walker T, Engel C, Kyriss T . Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg. 2007; 83(6):1940-5. DOI: 10.1016/j.athoracsur.2007.02.061. View

13.

Rodriguez-Panadero F, Montes-Worboys A . Mechanisms of pleurodesis. Respiration. 2012; 83(2):91-8. DOI: 10.1159/000335419. View

14.

Law M, Chan H, Leung C, Wong C, Lai H, Ha C . Marginal zone B-cell lymphoma mimicking extramedullary plasmacytoma and the clinical outcome after treatment. Arch Med Sci. 2017; 13(3):698-701. PMC: 5420643. DOI: 10.5114/aoms.2017.67290. View

15.

Shaw P, Agarwal R . Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004; (1):CD002916. DOI: 10.1002/14651858.CD002916.pub2. View

16.

Spych M, Gottwald L, Klonowicz M, Biegala M, Bibik R, Fijuth J . The analysis of prognostic factors affecting post-radiation acute reaction after conformal radiotherapy for non-small cell lung cancer. Arch Med Sci. 2012; 6(5):756-63. PMC: 3298346. DOI: 10.5114/aoms.2010.17092. View

17.

Psallidas I, Kalomenidis I, Porcel J, Robinson B, Stathopoulos G . Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016; 25(140):189-98. PMC: 9487241. DOI: 10.1183/16000617.0019-2016. View

18.

Dixit R, Agarwal K, Gokhroo A, Patil C, Meena M, Shah N . Diagnosis and management options in malignant pleural effusions. Lung India. 2017; 34(2):160-166. PMC: 5351359. DOI: 10.4103/0970-2113.201305. View

19.

Davies H, Lee Y . Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med. 2013; 19(4):374-9. DOI: 10.1097/MCP.0b013e3283615b67. View

20.

Roberts M, Neville E, Berrisford R, Antunes G, Ali N . Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010; 65 Suppl 2:ii32-40. DOI: 10.1136/thx.2010.136994. View